arrow
U

Umberto Basso

Veneto Institute of Oncology IOV-IRCCS
H指数:51
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Outcomes of DNA Damage Repair Altered Metastatic Castration-Resistant Prostate Cancer: Insights from FFPE-Based Genomic Profiling

真实世界DNA损伤修复改变转移性去势抵抗性前列腺癌的结局:基于FFPE的基因组分析启示

Cancers
IF4.4
2026-07-260
OA
Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection—Results of the MEET-URO 22 Study

SARS-CoV-2感染后能够维持/恢复持续抗肿瘤治疗的转移性前列腺癌患者的长期肿瘤学结局——MEET-URO 22研究的结果

Cancers
IF4.4
2026-01-150
OAAI
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study

同源重组修复基因检测变量及前列腺癌患者的诊断路径:一项多中心队列研究

2025-12-010
PRE
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

肾细胞癌辅助性帕博利珠单抗的实证据:多中心真实世界ARON-1研究的结果

2025-11-140
OAAI
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma

基于纳武利尤单抗的免疫疗法在真实世界老年转移性肾细胞癌患者中的疗效及通过Meet-URO评分进行的预后分层

2025-08-120
PRE
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON-1 study

帕博利珠单抗联合仑伐替尼在转移性肾细胞癌患者中的应用:国际ARON-1研究的真实世界证据

2025-05-090
OA
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial

奥拉帕利作为铂类耐药性生殖细胞肿瘤的挽救治疗:IGG-02期II临床试验

2025-05-010
PRE
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC

作为一线治疗用于mCRPC的雄激素受体信号抑制剂长期反应的预后因素

2025-04-280
PRE
The expanding role of next-generation imaging in prostate cancer management: a cross-sectional survey exploring the clinical practice of uro-oncologists in North-Eastern Italy; on behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est)

下一代成像在前列腺癌管理中不断扩展的作用:一项探索意大利东北部泌尿肿瘤学家临床实践的横断面调查;代表GUONE(Gruppo Uro-Oncologico del Nord-Est)

2025-03-120
OA
Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

G8老年综合评估筛查和Meet-URO评分在转移性肾细胞癌患者接受一线伊匹木单抗-纳武利尤单抗联合免疫治疗中的预后价值

2025-02-240
OA
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study

阿帕卢他胺在转移性去势敏感前列腺癌中的应用:多中心真实世界ARON-3研究的结果

2024-11-010
OAAI
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

转移性尿路上皮癌患者铂类化疗和Avelumab维持后的Enfortumab Vedotin: 来自ARON-2EV研究的回顾性数据

2024-10-011
OAAI
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)

晚期肾细胞癌 (ARON-1) 患者对一线免疫联合药物的真实世界原发性耐药

2024-09-171
PRE
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
2024-09-070
OA
Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study

BRCA1/2致病性变异位点与转移性去势抵抗性前列腺癌患者从PARP抑制剂中获益的关系:PROGRESS研究的结果

2024-09-010
PRE
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study)

转移性肾细胞癌患者的国际多中心真实世界注册表-meet-uro 33研究 (REGAL研究)

2024-06-246
OAAI
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study
2024-03-014
OAAI
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study

转移性前列腺癌老年患者日常生活的工具性活动: 来自meet-URO网络坚持前瞻性研究的结果

2024-02-281
OAAI
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

接受一线免疫治疗的转移性肾细胞癌患者基于红细胞的血液预后评分的外部验证

2024-02-163
OAAI